|drug1119||RT PCR SARS-CoV-2 Wiki||0.58|
|drug1666||standardized Lung Ultrasound (LUS) examination Wiki||0.58|
|drug1388||This is an online survey with no intervention. Wiki||0.58|
|drug1035||Placebo oral tablet Wiki||0.12|
|D011251||Pregnancy Complications, Infectious NIH||0.58|
|D011024||Pneumonia, Viral NIH||0.08|
|D003141||Communicable Diseases NIH||0.06|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D018352||Coronavirus Infections NIH||0.03|
There are 3 clinical trials
Currently there is a great need for an accurately and rapid assessment of patients suspected for Covid-19. Like CT, Lung Ultrasound (LUS) examination can potentially help with the initial triage of patients but also help track the evolution of the disease. LUS can be used in every setting, including settings with limited infrastructure, allowing the reduction of disparities in trials participation. LUS is also a practical approach that can be used by obstetricians/gynecologists, who are the primary care givers in the labour and delivery room. The International Lung UltraSound Analysis (ILUSA) Study is an international multicenter prospective explorative observational study to assess the predictive value of LUS in Covid-19 suspected and diagnosed pregnant patients.
Description: The primary endpoint is diagnostic performance in terms of the area under the receiver operating characteristic curve (AUC, also known as the c-statistic) and sensitivity and specificity with regard to the prediction of poor outcome. Outcome at one week from admission: good outcome includes discharge or inpatient breathing in free air; poor outcome includes patient with oxygen support, patients with CPAP/ high oxygen flow cannula, or patient with endotracheal intubation during the week.Measure: Diagnostic performance of LUS to predict poor outcome Time: outcome one week after enrollment into the study
The purpose of this study is to assess the health and wellbeing of pregnant and recently pregnant women during the COVID-19 pandemic using an online survey.
Description: Post-traumatic Stress Disorder (PTSD) Symptoms will be assessed by the Impact of Events Scale-6. This scale includes a total of six items: two items from each of the three subscales of the measure, namely intrusion, hyperarousal and avoidance. Participants will be asked to report their PTSD symptoms in the past 7 days on a Likert Scale ranging from 0 (not at all) to 4 (extremely).Measure: Post-traumatic Stress Disorder Time: Anytime during pregnancy or within 6 months after given birth.
Description: Symptoms of anxiety and depression will be measured by the Patient Health Questionnaire-4 (PHQ-4) which combines two ultrabrief screeners: the PHQ-2 and the Generalised Anxiety Disorder Scale. Participants will be asked to report their symptoms of depression and anxiety in the past 2 weeks on a Likert Scale from 0 (not at all) to 3 (nearly every day) for a maximum score of 12.Measure: Anxiety and Depression Time: Anytime during pregnancy or within 6 months after given birth.
This is a multicenter prospective study that aims to investigate the clinical impact of SARS-CoV-2 infection in pregnant women, pregnancy outcomes and perinatal transmission.
Description: Positive Sars-Cov-2 RT PCR in nasopharyngeal/oral swab tests or presence of IgM in blood samplesMeasure: SARS-CoV-2 Neonatal Infection Time: 7 days
Description: stillbirths and deaths in the first week of lifeMeasure: Perinatal mortality Time: 35 weeks
Description: maternal ICU admission due to COVID-19Measure: ICU maternal admission Time: 35 weeks
Description: Newborn 5 minute Apgar Score < 7Measure: 5 minute Apgar Score < 7 Time: 1 day
Description: Delivery between 24 and 36 weeksMeasure: Preterm labour Time: 35 weeks
Description: Preterm premature rupture of the membranes between 24 and 36 weeksMeasure: PPROM Time: 35 weeks
Description: spontaneous pregnancy loss before 24 weeksMeasure: Miscarriage Time: 14 weeks